Xilio Therapeutics (XLO)
(Delayed Data from NSDQ)
$0.94 USD
-0.07 (-7.41%)
Updated Jul 24, 2024 03:59 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Xilio Therapeutics, Inc. - Hold
Zacks' proprietary data indicates that Xilio Therapeutics, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the XLO shares relative to the market in the next few months. In addition, Xilio Therapeutics, Inc. has a VGM Score of D (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading style). Valuation metrics show that Xilio Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of XLO, demonstrate its potential to underperform the market. It currently has a Growth Score of B. Recent price changes and earnings estimate revisions indicate this stock lacks momentum and would be a lackluster choice for momentum investors.